The efficacy of adjuvant nivolumab in resected esophageal or gastroesophageal junction cancers: A single-center real-life data experience.

Category Primary study
ConferenceASCO ANNUAL MEETING
Year 2025
This article has no abstract
Epistemonikos ID: c5059a71cf92a1b0ae71887e9765c0f2637bf32b
First added on: Apr 04, 2026